Abstract
Eating disorders and some forms of obesity are characterized by addictive-like, compulsive eating behavior which contains numerous similarities with compulsive drug use. Food intake is in part mediated by reward and reinforcement processes that can become dysregulated in these disorders. Additionally, impairments in inhibitory control regulation of reward-related responding can cause or further exacerbate binge and compulsive eating. Dysfunctions in two neurotransmitter systems in the mesocorticolimbic pathway, dopamine and glutamate, are thought to contribute to maladaptive eating behaviors. The trace amine associated receptor 1 (TAAR1) system is a promising therapeutic target for compulsive eating behavior due to the role of TAAR1 in synaptic transmission and in the modulation of dopaminergic and glutamatergic signaling. In support of this notion, the TAAR1 agonist RO5256390 was found to decrease the reinforcing effects of palatable food-cues and to reduce binge-like and compulsive-like eating of palatable food. Additionally, prolonged, intermittent access to palatable food was shown to downregulate TAAR1 in the prefrontal cortex, suggesting a potential role for TAAR1 signaling in inhibitory control processes. Research into the role of TAAR1 in addiction, including TAAR1’s ability to modulate psychostimulant reward and reinforcement, bolsters support for TAAR1 agonism as a pharmacological treatment for compulsive eating and other addictive behaviors. This review summarizes the evidence for TAAR1 agonism as a promising therapeutic for compulsive eating behavior as well as the hypothesized mechanism responsible for these effects.
Introduction
Eating disorders, including binge eating disorder (BED), bulimia nervosa (BN), anorexia nervosa (AN), ‘food addiction,’ and some forms of obesity are associated with significant economic and social costs (; Whiteford et al., 2013) and limited effective treatments are available (). A main driver of eating disorders is thought to be the increased availability of highly palatable and highly reinforcing food, rich in fats and sugars, which results in addictive-like overconsumption (). Dysfunctions in dopaminergic and glutamatergic neurocircuitries that mediate reward/reinforcement and inhibitory control processes are hypothesized to drive binge and compulsive eating behaviors (). The trace amine-associated receptor 1 (TAAR1) system has recently gained attention as a neuromodulator of dopaminergic and glutamatergic signaling, making it a very promising therapeutic target for addiction-like disorders. To date, while a multitude of research has investigated the role of TAAR1 in drug addiction (Thorn et al., 2014; ; ; ), very little is known about the modulatory role of TAAR1 in the rewarding properties of food. The scope of this mini-review is to discuss published studies pertaining to TAAR1 in relation to food reward.
TAAR1 Agonism Blocks Binge Eating of Palatable Food
Binge eating is defined as consuming large quantities of food in a short period of time accompanied by a loss of control over food intake (; ). In a typical binge eating episode, palatable food, usually rich in fats and sugars, is consumed at a very high eating rate. Binge eating is a central feature of BED, BN, and some forms of AN, and is also highly prevalent in obese individuals (; ). Binge eating is driven largely by hedonic reward mechanisms and results in similar neurochemical consequences as drugs of abuse (; ; ; ). Thus, the ability of TAAR1 agonism to reduce psychostimulant reward and to modulate the mesolimbic dopaminergic signaling (; Xie et al., 2007; ) led to its investigation as a potential therapeutic to decrease binge-like eating of palatable food intake in rodents (). The effects of TAAR1 agonism were investigated in a rodent model of binge-like eating induced by limiting access to a highly palatable, sugary diet for 1 h/day (), a paradigm which induces both binge eating and heightened eating rate in rodents. In this study, the selective TAAR1 agonist RO5256390 dose-dependently blocked binge-like eating of the palatable diet. The highest dose of 10 mg/kg was sufficient to reduce intake of the palatable diet to equivalent levels of standard chow intake in control subjects, which notably was not affected by the drug treatment. Interestingly, selective drug effects on palatable food intake were also observed when the doses of 1 and 3 mg/kg were injected. Furthermore, treatment with RO5256390 decreased the feeding rate for the highly palatable food.
In a different study, RO5256390 was also able to decrease, as well as slow down, responding for chocolate flavored pellets in rats (). In this study, only the highest dose of RO5256390 (10 mg/kg) was able to affect responding for the chocolate pellets, while treatment with 3 mg/kg of RO5256390 did not reduce food responding. Therefore, the two mentioned studies reported dissimilar sensitivity of the drug effect at the different doses tested, which is likely attributable to differences in experimental design: capped daily intake at 40 pellets per session, while had no limit in responses, allowing for a more sensitive measurement of TAAR1 effects even at lower doses.
Another study, performed in mice, reported similar effects of TAAR1 agonism. R5166017 (0.3 mg/kg) was able to reduce high fat diet intake in a model of diet-induced obesity (). Following a 10-h fast, acute injection of the TAAR1 agonist reduced the total number of meals and duration of meals during the first hour compared to obese mice injected with vehicle as well as TAAR1 knockout (KO) mice (). Additionally, subchronic treatment with the TAAR1 agonist (admixed in the diet to deliver an approximate dose of 3.5 mg/kg) reduced daily intake of the high fat diet by 25% and reduced body weight by 6.6% in obese mice ().
Interestingly, partial agonism at TAAR1 (by RO5203648 or RO5263397) has been shown to have no effects on food self-administration () or to enhance responding for food under a progressive ratio schedule (, ). Selective TAAR1 full agonists are known to decrease the frequency of dopamine neuron firing in the VTA through activation of inwardly rectifying K+ channels (). However, partial TAAR1 agonism () as well as TAAR1 antagonism () have opposite effects, suggesting that TAAR1 maintains a degree of baseline or constitutive activity. Thus, while the divergence in effects on food reward between the full and partial TAAR1 agonism is not fully elucidated, we hypothesize that TAAR1 full agonist effect on binge eating lies in its ability to reduce VTA dopaminergic activity (see Figure 1).
FIGURE 1
TAAR1 Agonism Reduces the Reinforcing Properties of Palatable Food-Associated Cues
Environmental food-associated stimuli exert a powerful control over behavior and can robustly enhance the desire to binge, even in satiated humans (
A procedure used in the preclinical laboratory setting to assess the magnitude of influence of a conditioned stimulus (CS) over food or drug-seeking behavior is the second-order schedule of reinforcement (
Another paradigm used to test the rewarding properties of food or drugs and the ability of paired contextual cues to drive behavior is the conditioned place preference (CPP) test. In animals with a history of binge-eating a highly palatable, sugary diet, following conditioning, tactile and visual cues associated with the highly palatable food are able to induce a strong place preference, unlike stimuli associated to the standard chow diet (Velazquez-Sanchez et al., 2015;
These experiments show that TAAR1 agonism greatly reduced the strength of palatable-food associated stimuli in driving behavior in rats with a history of binge eating. Though exact mechanisms have not yet been examined specifically for palatable food-cues, studies have found that the ability of TAAR1 to decrease the ability of drug-paired cues to elicit cocaine-seeking behavior can be pinpointed the ventral tegmental area and the prelimbic region of the medial prefrontal cortex (mPFC) as critical sites of action for TAAR1 in reducing cue-induced seeking behavior and drug-related memory expression (
TAAR1 Agonism Blocks Compulsive-Like Eating
Compulsivity is a behavioral construct observed in different disorders, including drug addiction and disorders of pathological eating, where there is a loss of control over behavior that results in continued use despite incurring negative consequences (e.g., medical, psychological, emotional, and social impairment) (
To test continued overeating despite consequences in animals, a commonly used paradigm is the light/dark conflict test, where feeding is typically suppressed in control rats when they face the aversive bright compartment of the light/dark box. However, rats with a history of intermittent access to palatable food will compulsively consume the palatable diet in face of the risky environment (
Compulsivity shares some commonalities with impulsivity in that both constructs involve a dysfunction in inhibitory control, mediated by frontal cortex projections to subcortical regions (
Binge-Like Eating Decreases TAAR1 Protein Expression in Prefrontal Cortices
Inhibitory control processes are largely governed by prefrontocortical circuits, and dysfunctions in this pathway are thought to underlie the loss of control and continued intake despite aversive consequences (Tomasi and Volkow, 2013; Volkow et al., 2013;
Trace Amine Associated Receptor 1 modulation of prefrontocortical activity is one hypothesized mechanism for the effects on compulsive eating and other addictive behaviors. TAAR1 protein expression was decreased in the mPFC of animals with a history of binge eating of palatable food, compared to controls fed a standard chow diet (
Discussion and Conclusions
The rise of eating-related disorders, including some forms of obesity, BED, BN, AN, and food addiction has prompted much research, and has resulted in a few medications with varying levels of effectiveness (
Importantly, TAAR1 effects on compulsive, binge eating are being driven by direct actions on food reward mechanisms, rather than homeostatic needs. Evidence for this is twofold. The first is that no food restriction or deprivation was used in the above-summarized studies showing its efficacy (
Though TAAR1 agonism effects on binge, compulsive eating are not being mediated by homeostatic mechanisms, it is interesting to note that TAAR1 activation has been studied for its metabolic effects in models of obesity and diabetes (
The TAAR1 full agonist RO5256390 was not found to have any effects on anxiety-like (
Statements
Author contributions
All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.
Funding
This work was supported by the National Institutes of Health [Grant Nos. DA030425 (PC), MH091945 (PC), MH093650 (VS), AA024439 (VS), AA025038 (VS), and DA044664 (CM)]; the Peter Paul Career Development Professorships (PC); the McManus Charitable Trust (VS); and the Burroughs Wellcome Fund (CM) through the Transformative Training Program in Addiction Sciences [Grant No. 1011479]. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders.Washington, DC: American Psychiatric Association. 10.1176/appi.books.9780890425596
2
AvenaN. M.RadaP.HoebelB. G. (2008). Evidence for sugar addiction: behavioral and neurochemical effects of intermittent, excessive sugar intake.Neurosci. Biobehav. Rev.3220–39. 10.1016/j.neubiorev.2007.04.019
3
BalodisI. M.MolinaN. D.KoberH.WorhunskyP. D.WhiteM. A.RajitaS.et al (2013). Divergent neural substrates of inhibitory control in binge eating disorder relative to other manifestations of obesity.Obesity21367–377. 10.1002/oby.20068
4
BancaP.HarrisonN. A.VoonV. (2016). Compulsivity across the pathological misuse of drug and non-drug rewards.Front. Behav. Neurosci.10:154. 10.3389/fnbeh.2016.00154
5
BarkerJ. M.TaylorJ. R.ChandlerL. J. (2014). A unifying model of the role of the infralimbic cortex in extinction and habits.Learn. Mem.21441–448. 10.1101/lm.035501.114
6
BelinD.MarA. C.DalleyJ. W.RobbinsT. W.EverittB. J. (2008). High impulsivity predicts the switch to compulsive cocaine-taking.Science3201352–1355. 10.1126/science.1158136
7
BergerD. F.SagvoldenT. (1998). Sex differences in operant discrimination behaviour in an animal model of attention-deficit hyperactivity disorder.Behav. Brain Res.9473–82. 10.1016/S0166-4328(97)00171-X
8
BlasioA.IemoloA.SabinoV.PetrosinoS.SteardoL.RiceK. C.et al (2013). Rimonabant precipitates anxiety in rats withdrawn from palatable food: role of the central amygdala.Neuropsychopharmacology382498–2507. 10.1038/npp.2013.153
9
BorowskyB.AdhamN.JonesK. A.RaddatzR.ArtymyshynR.OgozalekK. L.et al (2001). Trace amines: identification of a family of mammalian G protein-coupled receptors.Proc. Natl. Acad. Sci. U.S.A.988966–8971. 10.1073/pnas.151105198
10
BoswellR. G.KoberH. (2016). Food cue reactivity and craving predict eating and weight gain: a meta-analytic review.Obes. Rev.17159–177. 10.1111/obr.12354
11
BradaiaA.TrubeG.StalderH.NorcrossR. D.OzmenL.WettsteinJ. G.et al (2009). The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system.Proc. Natl. Acad. Sci. U.S.A.10620081–20086. 10.1073/pnas.0906522106
12
CorwinR. L.AvenaN. M.BoggianoM. M. (2011). Feeding and reward: perspectives from three rat models of binge eating.Physiol. Behav.10487–97. 10.1016/j.physbeh.2011.04.041
13
CottoneP.SabinoV.RobertoM.BajoM.PockrosL.FrihaufJ. B.et al (2009). CRF system recruitment mediates dark side of compulsive eating.Proc. Natl. Acad. Sci. U.S.A.10620016–20020. 10.1073/pnas.0908789106
14
CottoneP.SabinoV.SteardoL.ZorrillaE. P. (2008). Opioid-dependent anticipatory negative contrast and binge-like eating in rats with limited access to highly preferred food.Neuropsychopharmacology33524–535. 10.1038/sj.npp.1301430
15
CottoneP.WangX.ParkJ. W.ValenzaM.BlasioA.KwakJ.et al (2012). Antagonism of sigma-1 receptors blocks compulsive-like eating.Neuropsychopharmacology372593–2604. 10.1038/npp.2012.89
16
CowdreyF. A.ParkR. J.HarmerC. J.McCabeC. (2011). Increased neural processing of rewarding and aversive food stimuli in recovered anorexia nervosa.Biol. Psychiatry70736–743. 10.1016/j.biopsych.2011.05.028
17
DalleyJ. W.EverittB. J.RobbinsT. W. (2011). Impulsivity, compulsivity, and top-down cognitive control.Neuron69680–694. 10.1016/j.neuron.2011.01.020
18
DavisC. (2013a). From passive overeating to “food addiction”: a spectrum of compulsion and severity.ISRN Obes.2013:435027. 10.1155/2013/435027
19
DavisC. (2013b). A narrative review of binge eating and addictive behaviors: shared associations with seasonality and personality factors.Front. Psychiatry4:183. 10.3389/fpsyt.2013.00183
20
DavisC.CarterJ. C. (2009). Compulsive overeating as an addiction disorder. A review of theory and evidence.Appetite531–8. 10.1016/j.appet.2009.05.018
21
de ZwaanM. (2001). Binge eating disorder and obesity.Int. J. Obes. Relat. Metab. Disord.25(Suppl. 1)S51–S55. 10.1038/sj.ijo.0801699
22
DimitropoulosA.TkachJ.HoA.KennedyJ. (2012). Greater corticolimbic activation to high-calorie food cues after eating in obese vs. normal-weight adults.Appetite58303–312. 10.1016/j.appet.2011.10.014
23
DingemansA. E.van FurthE. F. (2012). Binge Eating Disorder psychopathology in normal weight and obese individuals.Int. J. Eat. Disord.45135–138. 10.1002/eat.20905
24
DoreR.ValenzaM.WangX.RiceK. C.SabinoV.CottoneP. (2014). The inverse agonist of CB1 receptor SR141716 blocks compulsive eating of palatable food.Addict. Biol.19849–861. 10.1111/adb.12056
25
EspinozaS.LignaniG.CaffinoL.MaggiS.SukhanovI.LeoD.et al (2015). TAAR1 modulates cortical glutamate NMDA receptor function.Neuropsychopharmacology402217–2227. 10.1038/npp.2015.65
26
EverittB. J.RobbinsT. W. (2000). Second-order schedules of drug reinforcement in rats and monkeys: measurement of reinforcing efficacy and drug-seeking behaviour.Psychopharmacology15317–30. 10.1007/s002130000566
27
EverittB. J.RobbinsT. W. (2005). Neural systems of reinforcement for drug addiction: from actions to habits to compulsion.Nat. Neurosci.81481–1489. 10.1038/nn1579
28
FergusonK. J.SpitzerR. L. (1995). Binge eating disorder in a community-based sample of successful and unsuccessful dieters.Int. J. Eat. Disord.18167–172.
29
FerragudA.HowellA. D.MooreC. F.TaT. L.HoenerM. C.SabinoV.et al (2017). The trace amine-associated receptor 1 agonist RO5256390 blocks compulsive, binge-like eating in rats.Neuropsychopharmacology421458–1470. 10.1038/npp.2016.233
30
FlamentM. F.BissadaH.SpettigueW. (2012). Evidence-based pharmacotherapy of eating disorders.Int. J. Neuropsychopharmacol.15189–207. 10.1017/S1461145711000381
31
FurlongT. M.JayaweeraH. K.BalleineB. W.CorbitL. H. (2014). Binge-like consumption of a palatable food accelerates habitual control of behavior and is dependent on activation of the dorsolateral striatum.J. Neurosci.345012–5022. 10.1523/JNEUROSCI.3707-13.2014
32
GearhardtA. N.CorbinW. R.BrownellK. D. (2009). Preliminary validation of the Yale Food Addiction Scale.Appetite52430–436. 10.1016/j.appet.2008.12.003
33
GiulianoC.CottoneP. (2015). The role of the opioid system in binge eating disorder.CNS Spectr.20537–545. 10.1017/S1092852915000668
34
GiulianoC.RobbinsT. W.NathanP. J.BullmoreE. T.EverittB. J. (2012). Inhibition of opioid transmission at the μ-opioid receptor prevents both food seeking and binge-like eating.Neuropsychopharmacology372643–2652. 10.1038/npp.2012.128
35
GoodmanD. W. (2010). Lisdexamfetamine dimesylate (vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorder.P T35273–287.
36
HarknessJ. H.ShiX.JanowskyA.PhillipsT. J. (2015). Trace amine-associated receptor 1 regulation of methamphetamine intake and related traits.Neuropsychopharmacology402175–2184. 10.1038/npp.2015.61
37
HendrikseJ. J.CachiaR. L.KotheE. J.McPhieS.SkouterisH.HaydenM. J. (2015). Attentional biases for food cues in overweight and individuals with obesity: a systematic review of the literature.Obes. Rev.16424–432. 10.1111/obr.12265
38
Hone-BlanchetA.FecteauS. (2014). Overlap of food addiction and substance use disorders definitions: analysis of animal and human studies.Neuropharmacology8581–90. 10.1016/j.neuropharm.2014.05.019
39
HudsonJ. I.McElroyS. L.Ferreira-CornwellM. C.RadewonukJ.GasiorM. (2017). Efficacy of lisdexamfetamine in adults with moderate to severe binge-eating disorder: a randomized clinical trial.JAMA Psychiatry74903–910. 10.1001/jamapsychiatry.2017.1889
40
IemoloA.BlasioA.St CyrS. A.JiangF.RiceK. C.SabinoV.et al (2013). CRF-CRF1 receptor system in the central and basolateral nuclei of the amygdala differentially mediates excessive eating of palatable food.Neuropsychopharmacology382456–2466. 10.1038/npp.2013.147
41
JentschJ. D.TaylorJ. R. (1999). Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli.Psychopharmacology146373–390. 10.1007/PL00005483
42
LawrenceN. S.HintonE. C.ParkinsonJ. A.LawrenceA. D. (2012). Nucleus accumbens response to food cues predicts subsequent snack consumption in women and increased body mass index in those with reduced self-control.Neuroimage63415–422. 10.1016/j.neuroimage.2012.06.070
43
LehnertT.SonntagD.KonnopkaA.Riedel-HellerS.KonigH. H. (2013). Economic costs of overweight and obesity.Best Pract. Res. Clin. Endocrinol. Metab.27105–115. 10.1016/j.beem.2013.01.002
44
LiuJ. F.SiemianJ. N.SeamanR.Jr.ZhangY.LiJ. X. (2017). Role of TAAR1 within the subregions of the mesocorticolimbic dopaminergic system in cocaine-seeking behavior.J. Neurosci.37882–892. 10.1523/JNEUROSCI.2006-16.2016
45
LiuJ. F.ThornD. A.ZhangY.LiJ. X. (2016). Effects of trace amine-associated receptor 1 agonists on the expression, reconsolidation, and extinction of cocaine reward memory.Int. J. Neuropsychopharmacol.19:pyw009. 10.1093/ijnp/pyw009
46
MeuleA.LutzA.VogeleC.KublerA. (2012). Women with elevated food addiction symptoms show accelerated reactions, but no impaired inhibitory control, in response to pictures of high-calorie food-cues.Eat. Behav.13423–428. 10.1016/j.eatbeh.2012.08.001
47
MillerG. M.VerricoC. D.JassenA.KonarM.YangH.PanasH.et al (2005). Primate trace amine receptor 1 modulation by the dopamine transporter.J. Pharmacol. Exp. Ther.313983–994. 10.1124/jpet.105.084459
48
MooreC. F.PancieraJ. I.SabinoV.CottoneP. (2017a). Neuropharmacology of compulsive eating.Philos. Trans. R. Soc. Lond. B Biol. Sci.373:20170024. 10.1098/rstb.2017.0024
49
MooreC. F.SabinoV.KoobG. F.CottoneP. (2017b). Neuroscience of compulsive eating behavior.Front. Neurosci.11:469. 10.3389/fnins.2017.00469
50
MooreC. F.SabinoV.KoobG. F.CottoneP. (2017c). Pathological overeating: emerging evidence for a compulsivity construct.Neuropsychopharmacology421375–1389. 10.1038/npp.2016.269
51
MoormanD. E.JamesM. H.McGlincheyE. M.Aston-JonesG. (2015). Differential roles of medial prefrontal subregions in the regulation of drug seeking.Brain Res.1628(Pt A)130–146. 10.1016/j.brainres.2014.12.024
52
MorrisM. J.BeilharzJ. E.ManiamJ.ReicheltA. C.WestbrookR. F. (2015). Why is obesity such a problem in the 21st century? The intersection of palatable food, cues and reward pathways, stress, and cognition.Neurosci. Biobehav. Rev.5836–45. 10.1016/j.neubiorev.2014.12.002
53
MyersK. P. (2017). Sensory-specific satiety is intact in rats made obese on a high-fat high-sugar choice diet.Appetite112196–200. 10.1016/j.appet.2017.01.013
54
NgL.DavisC. (2013). Cravings and food consumption in Binge Eating Disorder.Eat. Behav.14472–475. 10.1016/j.eatbeh.2013.08.011
55
NiehE. H.MatthewsG. A.AllsopS. A.PresbreyK. N.LepplaC. A.WichmannR.et al (2015). Decoding neural circuits that control compulsive sucrose seeking.Cell160528–541. 10.1016/j.cell.2015.01.003
56
PeiY.Asif-MalikA.HoenerM.CanalesJ. J. (2017). A partial trace amine-associated receptor 1 agonist exhibits properties consistent with a methamphetamine substitution treatment.Addict. Biol.221246–1256. 10.1111/adb.12410
57
PeiY.LeeJ.LeoD.GainetdinovR. R.HoenerM. C.CanalesJ. J. (2014). Activation of the trace amine-associated receptor 1 prevents relapse to cocaine seeking.Neuropsychopharmacology392299–2308. 10.1038/npp.2014.88
58
PeiY.MortasP.HoenerM. C.CanalesJ. J. (2015). Selective activation of the trace amine-associated receptor 1 decreases cocaine’s reinforcing efficacy and prevents cocaine-induced changes in brain reward thresholds.Prog. Neuropsychopharmacol. Biol. Psychiatry6370–75. 10.1016/j.pnpbp.2015.05.014
59
RaabS.WangH.UhlesS.ColeN.Alvarez-SanchezR.KunneckeB.et al (2016). Incretin-like effects of small molecule trace amine-associated receptor 1 agonists.Mol. Metab.547–56. 10.1016/j.molmet.2015.09.015
60
RadaP.AvenaN. M.HoebelB. G. (2005). Daily bingeing on sugar repeatedly releases dopamine in the accumbens shell.Neuroscience134737–744. 10.1016/j.neuroscience.2005.04.043
61
ReasD. L.GriloC. M. (2014). Current and emerging drug treatments for binge eating disorder.Expert Opin. Emerg. Drugs1999–142. 10.1517/14728214.2014.879291
62
RevelF. G.MoreauJ. L.GainetdinovR. R.BradaiaA.SotnikovaT. D.MoryR.et al (2011). TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity.Proc. Natl. Acad. Sci. U.S.A.1088485–8490. 10.1073/pnas.1103029108
63
RevelF. G.MoreauJ. L.GainetdinovR. R.FerragudA.Velazquez-SanchezC.SotnikovaT. D.et al (2012). Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics.Biol. Psychiatry72934–942. 10.1016/j.biopsych.2012.05.014
64
RevelF. G.MoreauJ. L.PouzetB.MoryR.BradaiaA.BuchyD.et al (2013). A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.Mol. Psychiatry18543–556. 10.1038/mp.2012.57
65
RobbinsT. W.CurranH. V.de WitH. (2012). Special issue on impulsivity and compulsivity.Psychopharmacology219251–252. 10.1007/s00213-011-2584-x
66
RobinsonM. J.BurghardtP. R.PattersonC. M.NobileC. W.AkilH.WatsonS. J.et al (2015). Individual differences in cue-induced motivation and striatal systems in rats susceptible to diet-induced obesity.Neuropsychopharmacology402113–2123. 10.1038/npp.2015.71
67
RossettiC.SpenaG.HalfonO.BoutrelB. (2014). Evidence for a compulsive-like behavior in rats exposed to alternate access to highly preferred palatable food.Addict. Biol.19975–985. 10.1111/adb.12065
68
SchmitzF.NaumannE.TrentowskaM.SvaldiJ. (2014). Attentional bias for food cues in binge eating disorder.Appetite8070–80. 10.1016/j.appet.2014.04.023
69
ShankL. M.Tanofsky-KraffM.NelsonE. E.ShomakerL. B.RanzenhoferL. M.HannallahL. M.et al (2015). Attentional bias to food cues in youth with loss of control eating.Appetite8768–75. 10.1016/j.appet.2014.11.027
70
SmithK. L.RaoR. R.Velazquez-SanchezC.ValenzaM.GiulianoC.EverittB. J.et al (2015). The uncompetitive N-methyl-D-aspartate antagonist memantine reduces binge-like eating, food-seeking behavior, and compulsive eating: role of the nucleus accumbens shell.Neuropsychopharmacology401163–1171. 10.1038/npp.2014.299
71
ThornD. A.JingL.QiuY.Gancarz-KauschA. M.GaluskaC. M.DietzD. M.et al (2014). Effects of the trace amine-associated receptor 1 agonist RO5263397 on abuse-related effects of cocaine in rats.Neuropsychopharmacology392309–2316. 10.1038/npp.2014.91
72
TomasiD.VolkowN. D. (2013). Striatocortical pathway dysfunction in addiction and obesity: differences and similarities.Crit. Rev. Biochem. Mol. Biol.481–19. 10.3109/10409238.2012.735642
73
van HuijsteeA. N.MansvelderH. D. (2014). Glutamatergic synaptic plasticity in the mesocorticolimbic system in addiction.Front. Cell. Neurosci.8:466. 10.3389/fncel.2014.00466
74
Velazquez-SanchezC.FerragudA.MooreC. F.EverittB. J.SabinoV.CottoneP. (2014). High trait impulsivity predicts food addiction-like behavior in the rat.Neuropsychopharmacology392463–2472. 10.1038/npp.2014.98
75
Velazquez-SanchezC.SantosJ. W.SmithK. L.FerragudA.SabinoV.CottoneP. (2015). Seeking behavior, place conditioning, and resistance to conditioned suppression of feeding in rats intermittently exposed to palatable food.Behav. Neurosci.129219–224. 10.1037/bne0000042
76
VickersS. P.GoddardS.BrammerR. J.HutsonP. H.HealD. J. (2017). Investigation of impulsivity in binge-eating rats in a delay-discounting task and its prevention by the d-amphetamine prodrug, lisdexamfetamine.J. Psychopharmacol.31784–797. 10.1177/0269881117691672
77
VolkowN. D.WangG. J.TomasiD.BalerR. D. (2013). The addictive dimensionality of obesity.Biol. Psychiatry73811–818. 10.1016/j.biopsych.2012.12.020
78
VolkowN. D.WiseR. A. (2005). How can drug addiction help us understand obesity?Nat. Neurosci.8555–560. 10.1038/nn1452
79
WhitefordH. A.DegenhardtL.RehmJ.BaxterA. J.FerrariA. J.ErskineH. E.et al (2013). Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.Lancet3821575–1586. 10.1016/S0140-6736(13)61611-6
80
World Health Organization (2000). Obesity: Preventing and Managing the Global Epidemic. Report of a WHO consultation.WHO Technical Report Series 894. Geneva: World Health Organization.
81
XieZ.WestmorelandS. V.BahnM. E.ChenG. L.YangH.VallenderE. J.et al (2007). Rhesus monkey trace amine-associated receptor 1 signaling: enhancement by monoamine transporters and attenuation by the D2 autoreceptor in vitro.J. Pharmacol. Exp. Ther.321116–127. 10.1124/jpet.106.116863
Summary
Keywords
binge eating, addiction, compulsive, prefrontal cortex, inhibitory control
Citation
Moore CF, Sabino V and Cottone P (2018) Trace Amine Associated Receptor 1 (TAAR1) Modulation of Food Reward. Front. Pharmacol. 9:129. doi: 10.3389/fphar.2018.00129
Received
14 December 2017
Accepted
06 February 2018
Published
27 February 2018
Volume
9 - 2018
Edited by
Damiana Leo, University of Mons, Belgium
Reviewed by
Amy Claire Reichelt, RMIT University, Australia; Fabrizio Sanna, Università degli Studi di Cagliari, Italy
Updates

Check for updates
Copyright
© 2018 Moore, Sabino and Cottone.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Pietro Cottone, [email protected]
This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.